Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease

Agrawal, Mukta; AJAZUDDIN, .; Tripathi, Dulal Krishna; Saraf, Swarnlata; Saraf, Shailendra; Antimisiaris, Sophia G.; Mourtas, Spyridon; Hammarlund‐Udenaes, Margareta; Alexander, Amit

doi:10.1016/j.jconrel.2017.05.019

Cited by 261 publications

(116 citation statements)

References 183 publications

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…12-17 Moreover, recent advances in the development of liposome-based immunization techniques have demonstrated effective potential in the treatment of AD. 28 Based on our previous studies, using active immunotherapy to reduce Aβ plaque accumulation, 12-17 here, we show a newly-developed vaccine tool kit to be applied to animal AD models in order to circumvent the previous vaccine failures in humans, due to an extensive T cell-mediated immune response. 29 The present EB101 vaccine tool kit features a novel, proven formulation that generates autoimmunity against Aβ1-42, and easily associates with the phospholipid-S1P-liposomes by the hydrationrehydration method.…”

Section: Eb101 Ad Vaccine Immunization Strategy In Tg Micementioning

confidence: 96%

A Vaccine Kit for Prevention and Therapy of Alzheimer’s Disease in a Transgenic Mouse Model

Carrera¹,

Vigo²,

Cacabelos³

2018

Journal of Exploratory Research in Pharmacology

View full text Add to dashboard Cite

IntroductionAlzheimer's disease (AD) is the most common type of dementia, affecting multiple brain functions. 1 The exact cause of AD is still unknown, although some factors are thought to increase the risk of developing this progressive neurological disease. These factors include increasing age, a genetic-risk family history, previous severe head injuries, adverse lifestyle and cardiovascular aspects. 2, 3 The neuropathological hallmarks in the affected brain are characterized by the accumulation of extracellular amyloid-β (Aβ) peptide in amyloid plaques and intracellular neurofibrillary tangles with hyperphosphorylated tau proteins and massive neuronal-synaptic loss, affecting particularly the neocortex, hippocampus and entorhinal regions. 4 In AD preclinical studies that have focused on basic research and drug discovery, animal models (mice in particular) are essential tools for uncovering biological mechanisms, validating molecular targets and screening potential immunization compounds. 5-7 Both transgenic (Tg) and nongenetically-modified mouse models enable access to different types of AD-like pathology in vivo, crucial for gaining knowledge on disease etiology and to study the multiple AD interventions measured by targeting biomarkers. Over the last decade, the scientific community has been taking advantage of the potential aspects of double-and triple-Tg mouse lines, used to study emergent therapies for the prevention and reduction of the neurodegenerative features of AD, in order to extrapolate later to human studies. 8 Among these, active and passive immunization procedures against Aβ have been widely inves- A Vaccine Kit for Prevention and Therapy of Alzheimer's Disease in a Transgenic Mouse Model

show abstract

Section: Eb101 Ad Vaccine Immunization Strategy In Tg Micementioning

confidence: 96%

A Vaccine Kit for Prevention and Therapy of Alzheimer’s Disease in a Transgenic Mouse Model

Carrera¹,

Vigo²,

Cacabelos³

2018

Journal of Exploratory Research in Pharmacology

View full text Add to dashboard Cite

show abstract

“…When the highly toxic exudates of enterotoxigenic strains of B. fragilis escape the microbial-dense environment of the human GI-tract they can produce substantial systemic inflammatory pathology with significant mortality and morbidity. B. fragilis proliferation is associated with, and causative for, bacteremia, brain and intraabdominal abscess, cellulitis, colitis, diabetic ulcer, diarrhea, necrotizing fasciitis, sepsis, peritonitis, septicemia, association with and the development of multiple pro-inflammatory bowel cancers, systemic infection and systemic inflammation, the development of neurological diseases involving inflammatory neurodegeneration, and those neurological disorders that display a significantly elevated incidence of atypical developmental programming against a background of aging (Leshchyns'ka and Sytnyk, 2016;Agrawal et al, 2017;Shivaji, 2017;Zhao et al, 2019). Very recently LPS-induced systemic inflammation has been associated with synaptic loss and cognitive decline in multiple human neurological disorders and in animal models, and a role for LPS-mediated microglial release of pro-inflammatory cytokines (such as IL-1β) based on both in vivo and primary culture studies in vitro (Sheppard et al, 2019;Zhao et al, 2019).…”

Section: Gi-tract Exudates-bf-lps and Fragilysinmentioning

confidence: 99%

Gastrointestinal (GI) Tract Microbiome-Derived Neurotoxins—Potent Neuro-Inflammatory Signals From the GI Tract via the Systemic Circulation Into the Brain

Lukiw

2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

“…with an aqueous core. [41][42][43] The basic properties of the liposomes like fluidity, rigidity, size and surface behavior may vary with the selection of lipid component and method of preparation. It was first discovered by a British scientist Alec Bangham in 1961.…”

Section: Liposomementioning

confidence: 99%

“…In the majority of cases, one of the ligands assists the transport across the BBB while others target the particular disease site in the brain. Along with higher therapeutic efficacy, 41,130 it may also be disseminated to the other normal tissues of the body and results in unwanted side effect. In addition, some of the drugs get released into the systemic circulation during the normal circulatory period.…”

Section: Premature Drug Releasementioning

confidence: 99%

<p>Recent expansions of novel strategies towards the drug targeting into the brain</p>

Alexander¹,

Agrawal²,

Uddin³

et al. 2019

IJN

Self Cite

111

View full text Add to dashboard Cite

The treatment of central nervous system (CNS) disorders always remains a challenge for the researchers. The presence of various physiological barriers, primarily the blood–brain barrier (BBB) limits the accessibility of the brain and hinders the efficacy of various drug therapies. Hence, drug targeting to the brain, particularly to the diseased cells by circumventing the physiological barriers is essential to develop a promising therapy for the treatment of brain disorders. Presently, the investigations emphasize the role of different nanocarrier systems or surface modified target specific novel carrier system to improve the efficiency and reduce the side effects of the brain therapeutics. Such approaches supposed to circumvent the BBB or have the ability to cross the barrier function and thus increases the drug concentration in the brain. Although the efficacy of novel carrier system depends upon various physiological factors like active efflux transport, protein corona of the brain, stability, and toxicity of the nanocarrier, physicochemical properties, patient-related factors and many more. Hence, to develop a promising carrier system, it is essential to understand the physiology of the brain and BBB and also the other associated factors. Along with this, some alternative route like direct nose-to-brain drug delivery can also offer a better means to access the brain without exposure of the BBB. In this review, we have discussed the role of various physiological barriers including the BBB and blood-cerebrospinal fluid barrier (BCSFB) on the drug therapy and the mechanism of drug transport across the BBB. Further, we discussed different novel strategies for brain targeting of drug including, polymeric nanoparticles, lipidic nanoparticles, inorganic nanoparticles, liposomes, nanogels, nanoemulsions, dendrimers, quantum dots, etc. along with the intranasal drug delivery to the brain. We have also illustrated various factors affecting the drug targeting efficiency of the developed novel carrier system.

show abstract

Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease

Cited by 261 publications

References 183 publications

A Vaccine Kit for Prevention and Therapy of Alzheimer’s Disease in a Transgenic Mouse Model

A Vaccine Kit for Prevention and Therapy of Alzheimer’s Disease in a Transgenic Mouse Model

Gastrointestinal (GI) Tract Microbiome-Derived Neurotoxins—Potent Neuro-Inflammatory Signals From the GI Tract via the Systemic Circulation Into the Brain

<p>Recent expansions of novel strategies towards the drug targeting into the brain</p>

Contact Info

Product

Resources

About